Dynocardia

Dynocardia is pioneering a novel wearable technology platform, ViTrack™, designed to provide continuous non-invasive blood pressure (cNIBP) monitoring via a wrist-worn device. The company, founded by a team from MIT and Tufts with early NIH support, is currently conducting clinical trials to validate its technology across critical care and other settings. Its platform has broad potential applications spanning hospital care, remote patient monitoring, and consumer wellness, positioning it to address a significant unmet need in cardiovascular management. Dynocardia is a private, pre-revenue company advancing a potentially disruptive medical device through clinical development.

ViTrack™: A wearable, wrist-worn platform using a proprietary optical touch-sensing technology to enable accurate, continuous, and non-invasive monitoring of blood pressure and other vital heart and lung functions without user intervention.

Competitors range from large incumbent medtech companies (e.g., Philips, GE Healthcare) with invasive and intermittent monitoring solutions to startups developing alternative non-invasive technologies (e.g., optical, piezoelectric). Dynocardia's differentiation lies in its unique optical touch-sensing approach and aim for clinical-grade, continuous data from a passive wrist-worn device.